Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 227

recruiting
3 982
countries
28
conditions
2 106

3 662 trials match your criteria

Malignant mast cell neoplasm

Not recruiting

Study on the Safety and Effects of Livmoniplimab and Budigalimab in Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab

Rheumatoid arthritis

Not recruiting

Study on Rosnilimab for Patients with Moderate to Severe Rheumatoid Arthritis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rosnilimab

Thrombotic microangiopathy

Not recruiting

Study on Ravulizumab for Patients with Thrombotic Microangiopathy After Stem Cell Transplant

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ravulizumab

Haemophilia A without inhibitors

Not recruiting

Study on the Effects and Safety of Emicizumab for Infants with Hemophilia A (Ages Birth to 12 Months)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Emicizumab

Malignant melanoma

Not recruiting

Study of Fianlimab and Cemiplimab for Patients with Untreated Advanced Melanoma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cemiplimab

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

B-cell lymphoma

Not recruiting

Long-term Study of Zanubrutinib for Patients with B-cell Blood Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib

Non-small cell lung cancer stage III+5

Not recruiting

Study Comparing Ociperlimab and Tislelizumab with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ociperlimab

Metabolic dysfunction-associated liver disease

Not recruiting

Study on GSK4532990 for Adults with Nonalcoholic Steatohepatitis (NASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:GSK4532990A

Transitional cell carcinoma

Not recruiting

Study on Nivolumab and Ipilimumab for Patients with Untreated Unresectable or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Haematological malignancy+1

Not recruiting

Study of Tislelizumab, Pamiparib, and Ociperlimab in Patients with Advanced Solid Tumors and Blood Cancers

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ociperlimab

Lupus nephritis+1

Not recruiting

Study of Ravulizumab for Adults with Lupus Nephritis or IgA Nephropathy

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.